Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
741-760 of 1,738 trials

Advanced Solid Tumors and Blood Cancer: Durvalumab and Tremelimumab Study

We are testing the safety and early effectiveness of Durvalumab alone and with Tremelimumab in children with advanced solid tumors and blood cancers. This study aims to find the best dosage and understand how these treatments work.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

HER2-Altered Cancers: Zongertinib Study

We are testing whether zongertinib can help people with advanced solid tumors that have HER2 mutations or overexpression. The study will evaluate its effectiveness, safety, and how patients respond to the treatment.

HER2-mutated or overexpressed/amplified solid tumorsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Meningococcal Disease: New Pentavalent Vaccine for Children

We are studying a new vaccine to see if it is safe and effective for healthy children, toddlers, and infants against meningococcal disease. The trial compares this vaccine with currently licensed options to evaluate immune responses.

Meningococcal Immunization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Pancreatic Cancer: SGM-101 Imaging Study

We are testing a new imaging agent to help surgeons better see pancreatic tumors during surgery. This study aims to improve the accuracy of tumor detection and assess the extent of cancer in patients who have received prior treatment.

Pancreatic Tumor3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Crohn's Disease: AZD7798 Treatment Study

We are investigating how well AZD7798 works and its safety for people with moderate to severe Crohn's disease. This study will help us understand its effects on disease activity and overall health.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Psilocybin Therapy for Depression in Serious Illnesses

We are studying whether medium/high doses of psilocybin can help reduce depression and anxiety in patients with COPD, ALS, MS, or APD. This research aims to improve their quality of life and support their caregivers.

Chronic Respiratory and Neurological Disorders≤3 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryPulmonology

Pancreatic Cancer: Organoid-Based Treatment Selection

We are studying whether lab-grown mini-tumors can help choose better post-surgery treatments for patients with resectable pancreatic cancer. This may improve recovery and outcomes after surgery.

Pancreatic Ductal Adenocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Heart Transplant in Children: Comparing Custodiol and Custodiol-N

We are studying the safety of two organ preservation solutions during heart transplants in children. This research aims to see which solution better supports recovery and overall health after surgery.

Heart Transplantation in Children>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyPediatrics

Locally Advanced NSCLC: New Chemoradiotherapy Approach

We are studying a new FDG-PET-based treatment for patients with locally advanced non-small cell lung cancer. The goal is to see if this method is safer and more effective than the standard treatment.

Stage III Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Interstitial Lung Disease: Rituximab and Mycophenolate Combination

We are studying a combination of rituximab and mycophenolate mofetil for patients with interstitial lung disease related to systemic sclerosis. The goal is to see if this treatment improves lung function and overall health compared to a placebo.

Lung Involvement in Systemic Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesPulmonologyRheumatology

Tau Imaging in Alzheimer's: Comparing PET Tracers

We are comparing three different PET tau tracers in volunteers to see which one best measures tau levels in the brain. This research may help improve diagnosis and treatment monitoring for Alzheimer's disease.

Cognitive Impairment>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Acute Myeloid Leukemia: KO-539 Treatment Study

We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.

Relapsed Acute Myeloid Leukemia≤3 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Solid Tumors: DF6002 Treatment Study

We are investigating the safety and effectiveness of DF6002, alone and with Nivolumab, for patients with advanced solid tumors. This study aims to find the best dose and understand how well the treatment works.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesOncology

B-Cell Acute Lymphoblastic Leukemia: Inotuzumab Ozogamicin Study

We are examining whether Inotuzumab can help adults with B-Cell Acute Lymphoblastic Leukemia achieve MRD negativity before stem cell transplantation. The study will also look at treatment safety and survival rates.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Obstructive Sleep Apnea: Sulthiam and Oral Appliance Study

We are studying whether adding the medication sulthiam to an oral appliance helps patients with obstructive sleep apnea who aren't getting enough relief from their current treatment. This trial will also look for specific biomarkers related to their condition.

Obstructive Sleep ApneaEfficacy phase (II)Investigational MedicinesInternal MedicinePulmonology

ANCA-Associated Vasculitis: LNP023 (iptacopan) Study

We are testing a new treatment for patients with active ANCA-associated vasculitis to see if it helps achieve lasting remission compared to standard care. The study will also evaluate its impact on disease relapse and kidney health.

Microscopic PolyangiitisGranulomatosis with Polyangiitis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Targeted Anti-Cancer Treatment: ProTarget Trial

We are studying how effective and safe targeted cancer drugs are for patients with advanced cancer and specific genetic markers. This research may help improve treatment options based on individual genetic profiles.

Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Prostate Cancer: Talazoparib and Enzalutamide Study

We are testing a combination of Talazoparib and Enzalutamide for patients with metastatic prostate cancer who have progressed after abiraterone. The study aims to evaluate its effectiveness and safety as a first-line treatment.

Metastatic Prostate CancerEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Non-Alcoholic Steatohepatitis: Namodenoson Study

We are testing a new oral medication, namodenoson, for individuals with Non-Alcoholic Steatohepatitis (NASH). The study aims to see if it improves liver health and to evaluate its safety.

Non-Alcoholic Steatohepatitis (NASH)6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine